影像学方法在宫颈癌同步放化疗预后及疗效评估中的研究进展
Research Progress on the Use of Imaging Methods in Prognosis and Efficacy Evaluation of Concurrent Chemoradiotherapy for Cervical Cancer
摘要: 文章旨在介绍计算机断层扫描(Computed Tomography, CT)、磁共振成像(Magnetic Resonance Imaging, MRI)、核医学技术(如PET-CT等)及影像组学对宫颈癌同步放化疗预后及疗效评估中的作用。同步放化疗是局部晚期宫颈癌(LACC)患者的首选治疗方案，能够显著提高患者的生存率。随着医学影像技术的不断发展，传统影像学检查方法，如CT、MRI、US以及PET-CT等，在宫颈癌同步放化疗预后及疗效评估中发挥了重要作用。新兴的影像组学利用人工智能对MRI影像进行定量分析，基于从宫颈癌患者影像中提取的高通量特征，来建立有关患者同步放化疗治疗预后及疗效评估的预测模型。多种影像学方法及影像组学联合应用形成的评估体系为宫颈癌同步放化疗预后及疗效评估提供了重要依据。
Abstract: This article aims to introduce the role of computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine technology (such as PET-CT), and imaging omics in the prognosis and efficacy evaluation of concurrent chemoradiotherapy for cervical cancer. Concurrent chemoradiotherapy is the preferred treatment for patients with locally advanced cervical cancer (LACC), which can significantly improve the survival rate of patients. With the continuous development of medical imaging technology, traditional imaging methods such as CT, MRI, US, and PET-CT have played an important role in the prognosis and efficacy evaluation of concurrent chemoradiotherapy for cervical cancer. The emerging imaging omics uses artificial intelligence to quantitatively analyze MRI images. Based on the high-throughput features extracted from cervical cancer patients’ images, it establishes a prediction model for the prognosis and efficacy evaluation of patients treated with concurrent chemoradiotherapy. The evaluation system formed by the combined application of a variety of imaging methods and imaging omics provides an important basis for the prognosis and efficacy evaluation of concurrent chemoradiotherapy for cervical cancer.
文章引用：王腾达, 王锐. 影像学方法在宫颈癌同步放化疗预后及疗效评估中的研究进展[J]. 临床医学进展, 2026, 16(2): 617-624. https://doi.org/10.12677/acm.2026.162431

参考文献

[1] Cohen, P.A., Jhingran, A., Oaknin, A. and Denny, L. (2019) Cervical Cancer. The Lancet, 393, 169-182. [Google Scholar] [CrossRef] [PubMed]
[2] 刘宗超, 李哲轩, 张阳, 周彤, 张婧莹, 游伟程, 潘凯枫, 李文庆. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[3] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[4] Luo, W. (2021) Predicting Cervical Cancer Outcomes: Statistics, Images, and Machine Learning. Frontiers in Artificial Intelligence, 4, Article ID: 627369. [Google Scholar] [CrossRef] [PubMed]
[5] Koh, W., Abu-Rustum, N.R., Bean, S., Bradley, K., Campos, S.M., Cho, K.R., et al. (2019) Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 64-84. [Google Scholar] [CrossRef] [PubMed]
[6] Kalaghchi, B., Abdi, R., Amouzegar-Hashemi, F., Esmati, E. and Alikhasi, A. (2016) Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer. Asian Pacific Journal of Cancer Prevention, 17, 287-291. [Google Scholar] [CrossRef] [PubMed]
[7] Hirakawa, M., Nagai, Y., Inamine, M., Kamiyama, K., Ogawa, K., Toita, T., et al. (2008) Predictive Factor of Distant Recurrence in Locally Advanced Squamous Cell Carcinoma of the Cervix Treated with Concurrent Chemoradiotherapy. Gynecologic Oncology, 108, 126-129. [Google Scholar] [CrossRef] [PubMed]
[8] Kuno, I., Takayanagi, D., Asami, Y., Murakami, N., Matsuda, M., Shimada, Y., Hirose, S., et al. (2021) TP53 Mutants and Non-HPV16/18 Genotypes Are Poor Prognostic Factors for Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer. Scientific Reports, 11, Article No. 19261. [Google Scholar] [CrossRef] [PubMed]
[9] Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R.G.P.M., Granton, P., et al. (2012) Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis. European Journal of Cancer, 48, 441-446. [Google Scholar] [CrossRef] [PubMed]
[10] Nam, H., Park, W., Huh, S., Bae, D., Kim, B., Lee, J., et al. (2007) The Prognostic Significance of Tumor Volume Regression during Radiotherapy and Concurrent Chemoradiotherapy for Cervical Cancer Using MRI. Gynecologic Oncology, 107, 320-325. [Google Scholar] [CrossRef] [PubMed]
[11] Kim, J., Kim, C.K., Park, B.K., Park, S.Y., Huh, S.J. and Kim, B. (2012) Dynamic Contrast-Enhanced 3-T MR Imaging in Cervical Cancer before and after Concurrent Chemoradiotherapy. European Radiology, 22, 2533-2539. [Google Scholar] [CrossRef] [PubMed]
[12] Kim, H.S., Kim, C.K., Park, B.K., Huh, S.J. and Kim, B. (2012) Evaluation of Therapeutic Response to Concurrent Chemoradiotherapy in Patients with Cervical Cancer Using Diffusion‐Weighted MR Imaging. Journal of Magnetic Resonance Imaging, 37, 187-193. [Google Scholar] [CrossRef] [PubMed]
[13] Park, J.J., Kim, C.K., Park, S.Y., Simonetti, A.W., Kim, E., Park, B.K., et al. (2014) Assessment of Early Response to Concurrent Chemoradiotherapy in Cervical Cancer: Value of Diffusion-Weighted and Dynamic Contrast-Enhanced MR Imaging. Magnetic Resonance Imaging, 32, 993-1000. [Google Scholar] [CrossRef] [PubMed]
[14] Park, J.J., Kim, C.K. and Park, B.K. (2015) Prediction of Disease Progression Following Concurrent Chemoradiotherapy for Uterine Cervical Cancer: Value of Post-Treatment Diffusion-Weighted Imaging. European Radiology, 26, 3272-3279. [Google Scholar] [CrossRef] [PubMed]
[15] Zheng, X., Guo, W., Dong, J. and Qian, L. (2020) Prediction of Early Response to Concurrent Chemoradiotherapy in Cervical Cancer: Value of Multi-Parameter MRI Combined with Clinical Prognostic Factors. Magnetic Resonance Imaging, 72, 159-166. [Google Scholar] [CrossRef] [PubMed]
[16] Liu, B., Ma, W., Zhang, G., Sun, Z., Wei, M., Hou, W., et al. (2020) Potentialities of Multi-B-Values Diffusion-Weighted Imaging for Predicting Efficacy of Concurrent Chemoradiotherapy in Cervical Cancer Patients. BMC Medical Imaging, 20, Article No. 97. [Google Scholar] [CrossRef] [PubMed]
[17] Vojtíšek, R., Baxa, J., Kovářová, P., Almortaza, A., Hošek, P., Sukovská, E., et al. (2021) Prediction of Treatment Response in Patients with Locally Advanced Cervical Cancer Using Midtreatment PET/MRI during Concurrent Chemoradiotherapy. Strahlentherapie und Onkologie, 197, 494-504. [Google Scholar] [CrossRef] [PubMed]
[18] Gu, K., Kim, C.K., Choi, C.H., Yoon, Y.C. and Park, W. (2019) Prognostic Value of ADC Quantification for Clinical Outcome in Uterine Cervical Cancer Treated with Concurrent Chemoradiotherapy. European Radiology, 29, 6236-6244. [Google Scholar] [CrossRef] [PubMed]
[19] Bian, H., Liu, F., Chen, S., Li, G., Song, Y., Sun, M., et al. (2019) Intravoxel Incoherent Motion Diffusion-Weighted Imaging Evaluated the Response to Concurrent Chemoradiotherapy in Patients with Cervical Cancer. Medicine, 98, e17943. [Google Scholar] [CrossRef] [PubMed]
[20] Yang, W., Qiang, J.W., Tian, H.P., Chen, B., Wang, A.J. and Zhao, J.G. (2017) Multi-Parametric MRI in Cervical Cancer: Early Prediction of Response to Concurrent Chemoradiotherapy in Combination with Clinical Prognostic Factors. European Radiology, 28, 437-445. [Google Scholar] [CrossRef] [PubMed]
[21] Lu, H., Wu, Y., Liu, X., Huang, H., Jiang, H., Zhu, C., et al. (2021) The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy. Cancer Management and Research, 13, 6065-6078. [Google Scholar] [CrossRef] [PubMed]
[22] Lee, J.E., Huh, S.J., Nam, H. and Ju, S.G. (2012) Early Response of Patients Undergoing Concurrent Chemoradiotherapy for Cervical Cancer: A Comparison of PET/CT and MRI. Annals of Nuclear Medicine, 27, 37-45. [Google Scholar] [CrossRef] [PubMed]
[23] Su, T., Lin, G., Huang, Y., Liu, F., Wang, C., Chao, A., et al. (2017) Comparison of Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Posttherapy Evaluation in Patients with Advanced Cervical Cancer Receiving Definitive Concurrent Chemoradiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 45, 727-734. [Google Scholar] [CrossRef] [PubMed]
[24] Dag, Z., Yilmaz, B., Dogan, A.K., Aksan, D.U., Ozkurt, H., Kızılkaya, H.O., et al. (2019) Comparison of the Prognostic Value of F-18 FDG PET/CT Metabolic Parameters of Primary Tumors and MRI Findings in Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy. Brachytherapy, 18, 154-162. [Google Scholar] [CrossRef] [PubMed]
[25] Chong, G.O., Jeong, S.Y., Park, S., Lee, Y.H., Lee, S., Hong, D.G., et al. (2015) Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy. PLOS ONE, 10, e0137743. [Google Scholar] [CrossRef] [PubMed]
[26] Ho, K.C., Fang, Y.H., Chung, H.W., Yen, T.C., Ho, T.Y., Chou, H.H., Hong, J.H., et al. (2016) A Preliminary Investigation into Textural Features of Intratumoral Metabolic Heterogeneity in (18)F-FDG PET for Overall Survival Prognosis in Patients with Bulky Cervical Cancer Treated with Definitive Concurrent Chemoradiotherapy. American Journal of Nuclear Medicine and Molecular Imaging, 6, 166-175.
[27] Chong, G.O., Lee, W.K., Jeong, S.Y., Park, S., Lee, Y.H., Lee, S., et al. (2017) Prognostic Value of Intratumoral Metabolic Heterogeneity on F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy. Oncotarget, 8, 90402-90412. [Google Scholar] [CrossRef] [PubMed]
[28] Sarabhai, T., Tschischka, A., Stebner, V., Nensa, F., Wetter, A., Kimmig, R., Forsting, M., et al. (2018) Simultaneous Multiparametric PET/MRI for the Assessment of Therapeutic Response to Chemotherapy or Concurrent Chemoradiotherapy of Cervical Cancer Patients: Preliminary Results. Clinical Imaging, 49, 163-168. [Google Scholar] [CrossRef] [PubMed]
[29] Xu, C., Sun, H., Du, S. and Xin, J. (2019) Early Treatment Response of Patients Undergoing Concurrent Chemoradiotherapy for Cervical Cancer: An Evaluation of Integrated Multi-Parameter PET-IVIM MR. European Journal of Radiology, 117, 1-8. [Google Scholar] [CrossRef] [PubMed]
[30] Rui, T.D., Dong, Y., Qing, L.S., Tong, R., et al. (2020) Volume Computed Tomography Perfusion as a Predictive Marker for Treatment Response to Concurrent Chemoradiotherapy in Cervical Cancer: A Prospective Study. Acta Radiologica, 62, 281-288. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, Y., Zhang, K., Jia, H., Xia, B., Zang, C., Liu, Y., et al. (2022) IVIM-DWI and MRI-Based Radiomics in Cervical Cancer: Prediction of Concurrent Chemoradiotherapy Sensitivity in Combination with Clinical Prognostic Factors. Magnetic Resonance Imaging, 91, 37-44. [Google Scholar] [CrossRef] [PubMed]
[32] Peiretti, M., Zapardiel, I., Zanagnolo, V., Landoni, F., Morrow, C.P. and Maggioni, A. (2012) Management of Recurrent Cervical Cancer: A Review of the Literature. Surgical Oncology, 21, e59-e66. [Google Scholar] [CrossRef] [PubMed]
[33] Fagundes, H., Perez, C.A., Grigsby, P.W. and Lockett, M.A. (1992) Distant Metastases after Irradiation Alone in Carcinoma of the Uterine Cervix. International Journal of Radiation Oncology∙Biology∙Physics, 24, 197-204. [Google Scholar] [CrossRef] [PubMed]
[34] Gao, S., Du, S., Lu, Z., Xin, J., Gao, S. and Sun, H. (2019) Multiparametric PET/MR (PET and MR-IVIM) for the Evaluation of Early Treatment Response and Prediction of Tumor Recurrence in Patients with Locally Advanced Cervical Cancer. European Radiology, 30, 1191-1201. [Google Scholar] [CrossRef] [PubMed]
[35] Tseng, J., Yen, M., Twu, N., Lai, C., Horng, H., Tseng, C., et al. (2010) Prognostic Nomogram for Overall Survival in Stage IIB-IVA Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy. American Journal of Obstetrics and Gynecology, 202, 174.e1-174.e7. [Google Scholar] [CrossRef] [PubMed]
[36] Paskeh, M.D.A., Mirzaei, S., Gholami, M.H., Zarrabi, A., Zabolian, A., Hashemi, M., et al. (2021) Cervical Cancer Progression Is Regulated by SOX Transcription Factors: Revealing Signaling Networks and Therapeutic Strategies. Biomedicine & Pharmacotherapy, 144, Article ID: 112335. [Google Scholar] [CrossRef] [PubMed]
[37] Tewari, K.S., Sill, M.W., Long, H.J., Penson, R.T., Huang, H., Ramondetta, L.M., et al. (2014) Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 370, 734-743. [Google Scholar] [CrossRef] [PubMed]
[38] Kim, T.H., Kim, M., Kim, B., Park, S., Ryu, S. and Cho, C. (2017) Prognostic Importance of the Site of Recurrence in Patients with Metastatic Recurrent Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 98, 1124-1131. [Google Scholar] [CrossRef] [PubMed]
[39] 谢鹏, 郭秋芬, 张师前. 复发性子宫颈癌的综合治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 499-503.
[40] Zhang, X., Gu, M., Zhu, J., Gu, R., Yang, B., Ji, S., et al. (2024) Prognostic Value of Naples Prognostic Score in Locally Advanced Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy. Biomolecules and Biomedicine, 25, 986-999. [Google Scholar] [CrossRef] [PubMed]
[41] Ming, C., Bai, X., Zhao, L., Yu, D., Wang, X. and Wu, Y. (2023) RPL24 as a Potential Prognostic Biomarker for Cervical Cancer Treated by Cisplatin and Concurrent Chemoradiotherapy. Frontiers in Oncology, 13, Article ID: 1131803. [Google Scholar] [CrossRef] [PubMed]
[42] Liu, T., Kong, W., Liu, Y. and Song, D. (2020) Efficacy and Prognostic Factors of Concurrent Chemoradiotherapy in Patients with Stage Ib3 and IIa2 Cervical Cancer. Ginekologia Polska, 91, 57-61. [Google Scholar] [CrossRef] [PubMed]
[43] Liu, Y.M., Ni, L.Q., Wang, S.S., Lv, Q.L., Chen, W.J. and Ying, S.P. (2018) Outcome and Prognostic Factors in Cervical Cancer Patients Treated with Surgery and Concurrent Chemoradiotherapy: A Retrospective Study. World Journal of Surgical Oncology, 16, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[44] Fujiwara, M., Isohashi, F., Mabuchi, S., Yoshioka, Y., Seo, Y., Suzuki, O., et al. (2014) Efficacy and Safety of Nedaplatin-Based Concurrent Chemoradiotherapy for FIGO Stage IB2-IVA Cervical Cancer and Its Clinical Prognostic Factors. Journal of Radiation Research, 56, 305-314. [Google Scholar] [CrossRef] [PubMed]
[45] Endo, D., Todo, Y., Okamoto, K., Minobe, S., Kato, H. and Nishiyama, N. (2015) Prognostic Factors for Patients with Cervical Cancer Treated with Concurrent Chemoradiotherapy: A Retrospective Analysis in a Japanese Cohort. Journal of Gynecologic Oncology, 26, 12-18. [Google Scholar] [CrossRef] [PubMed]
[46] Tangkananan, A., Thongkhao, P., Janmunee, N. and Hanprasertpong, J. (2022) Impact of Chemotherapy Cycles on Oncological Outcomes in Elders with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy. Journal of Medical Imaging and Radiation Oncology, 66, 1014-1021. [Google Scholar] [CrossRef] [PubMed]
[47] Liu, J., Tang, G., Zhou, Q. and Kuang, W. (2022) Outcomes and Prognostic Factors in Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy. Radiation Oncology, 17, Article No. 142. [Google Scholar] [CrossRef] [PubMed]
[48] Kim, H., Cho, W.K., Kim, Y.J., Kim, Y.S. and Park, W. (2020) Significance of the Number of High-Risk Factors in Patients with Cervical Cancer Treated with Radical Hysterectomy and Concurrent Chemoradiotherapy. Gynecologic Oncology, 157, 423-428. [Google Scholar] [CrossRef] [PubMed]
[49] Peng, Q., Chen, K., Li, J., Chen, L. and Ye, W. (2022) Analysis of Treatment Outcomes and Prognosis after Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer. Frontiers in Oncology, 12, Article ID: 926840. [Google Scholar] [CrossRef] [PubMed]
[50] Zhang, G., Miao, L., Wu, H., Zhang, Y. and Fu, C. (2021) Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients after Postoperative Extended-Field Concurrent Chemoradiotherapy. Technology in Cancer Research & Treatment, 20. [Google Scholar] [CrossRef] [PubMed]
[51] Lee, J.W. and Seol, K.H. (2021) Pretreatment Neutrophil-to-Lymphocyte Ratio Combined with Platelet-to-Lymphocyte Ratio as a Predictor of Survival Outcomes after Definitive Concurrent Chemoradiotherapy for Cervical Cancer. Journal of Clinical Medicine, 10, Article No. 2199. [Google Scholar] [CrossRef] [PubMed]
[52] Lee, H.J., Kim, J.M., Chin, Y.J., Chong, G.O., Park, S., Lee, Y.H., et al. (2019) Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy. Anticancer Research, 40, 451-458. [Google Scholar] [CrossRef] [PubMed]
[53] Zhang, X., Zhang, Q., Guo, J., Zhao, J., Xie, L., Zhang, J., et al. (2022) Added-Value of Texture Analysis of ADC in Predicting the Survival of Patients with 2018 FIGO Stage IIICr Cervical Cancer Treated by Concurrent Chemoradiotherapy. European Journal of Radiology, 150, Article ID: 110272. [Google Scholar] [CrossRef] [PubMed]
[54] Xin, W., Rixin, S., Linrui, L., Zhihui, Q., Long, L. and Yu, Z. (2024) Machine Learning-Based Radiomics for Predicting Outcomes in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy. Computers in Biology and Medicine, 177, Article ID: 108593. [Google Scholar] [CrossRef] [PubMed]
[55] Zhang, Y., Liu, L., Zhang, K., Su, R., Jia, H., Qian, L., et al. (2023) Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-Free Survival after Concurrent Chemoradiotherapy in Patients with Locally Advanced Cervical Cancer. Academic Radiology, 30, 499-508. [Google Scholar] [CrossRef] [PubMed]
[56] Xu, C., Liu, W., Zhao, Q., Zhang, L., Yin, M., Zhou, J., et al. (2023) CT-Based Radiomics Nomogram for Overall Survival Prediction in Patients with Cervical Cancer Treated with Concurrent Chemoradiotherapy. Frontiers in Oncology, 13, Article ID: 1287121. [Google Scholar] [CrossRef] [PubMed]
[57] Cho, H., Lee, E.S., Lee, J.K., Eo, J.S., Kim, S. and Hong, J.H. (2022) Prognostic Value of Textural Features Obtained from F-Fluorodeoxyglucose (F-18 FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients with Locally Advanced Cervical Cancer Undergoing Concurrent Chemoradiotherapy. Annals of Nuclear Medicine, 37, 44-51. [Google Scholar] [CrossRef] [PubMed]
[58] Ma, Y., Zhao, X. and Chen, X. (2024) Contrast-Enhanced Ultrasound Combined with Elastic Imaging for Predicting the Efficacy of Concurrent Chemoradiotherapy in Cervical Cancer: A Feasibility Study. Frontiers in Oncology, 14, Article ID: 1301900. [Google Scholar] [CrossRef] [PubMed]

为你推荐